✦ LIBER ✦

A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer (NSCLC)

✍ Scribed by Rudd, R.M; Gower, N.H; James, L.E; Gregory, W; Eisen, T.Q; Lee, S.M; Harper, P.G; Prendiville, J; Spiro, S.G

Book ID: 118569609
Publisher: Elsevier Science
Year: 2000
Tongue: English
Weight: 118 KB
Volume: 29
Category: Article
ISSN: 0169-5002
DOI: 10.1016/s0169-5002(00)80064-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemcitabine-cisplatin (GP) vs gemcitabin

Gemcitabine-cisplatin (GP) vs gemcitabine-carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a multicenter phase II randomized trial

✍ P. Mazzanti; C. Massacesi; R. Mattioli; R. Trivisonne; F. Buzzi; G. De Signoribu 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Phase II study with gemcitabine, ifosfam

Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer

✍ Chen, Yuh-Min; Perng, Reury-Perng; Whang-Peng, Jacqueline; Wu, Hsiao-Wei; Lin, W 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 58 KB

A phase II/III randomised comparison of

A phase II/III randomised comparison of gemcitabine/carboplatin (GC) with cisplatin/etoposide (PE) in patients with poor prognosis small cell lung cancer (SCLC)

✍ Robin, R.M; James, L.E; Gower, N.H; Gregory, W; Eisen, T.Q; Harper, P.G; Gilliga 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 211 KB

Phase II study of mitomycin, ifosfamide

Phase II study of mitomycin, ifosfamide and gemcitabin (MIG) in advanced non-small-cell lung cancer

✍ Möller, G; van Henten, A; ten Velde, G 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 121 KB

Phase II study with mitomycin, ifosfamid

Phase II study with mitomycin, ifosfamide and carboplatin in inoperable non-small cell lung cancer

✍ A. von Rohr; H. Anderson; R. McIntosh; N. Thatcher 📂 Article 📅 1991 🏛 Elsevier Science ⚖ 348 KB

Phase III trial of gemcitabine and carbo

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

✍ Sarah Danson; Mark R. Middleton; Kenneth J. O'Byrne; Mark Clemons; Malcolm Ranso 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 325 KB

## Abstract ## BACKGROUND The authors compared gemcitabine and carboplatin (GC) with mitomycin, ifosfamide, and cisplatin (MIC) or mitomycin, vinblastine, and cisplatin (MVP) in patients with advanced nonsmall cell lung carcinoma (NSCLC). The primary objective was survival. Secondary objectives we